REXO4

Across TCGA pan-cancer cohorts, REXO4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated REXO4 data layer compared with 30 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher REXO4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated REXO4 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where REXO4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.387	0.639	.003	24	view →
CCRCC	OS	Median	IV	0.123	0.785	.009	15	view →
LSCC	DFS	Tertile	II,III,IV	0.838	0.516	.033	5	view →
GBM	OS	Tertile	All	0.557	0.237	.043	2	view →
HNSC	DFS	Median	All	0.981	0.921	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

REXO4–PDAC (OS)

Open the PDAC breakdown →